Welcome to our dedicated page for Celularity news (Ticker: CELU), a resource for investors and traders seeking the latest updates and insights on Celularity stock.
Celularity Inc. reports developments in regenerative and cellular medicine, including longevity-focused programs, placental-derived cell therapies and commercial regenerative medicine products such as Biovance and Biovance 3L. Company news also covers clinical and coverage-related updates, operating and financial results, capital-structure actions and governance matters.
Recurring corporate updates include periodic-reporting status, Nasdaq compliance, tax-credit monetization, material agreements and shareholder matters. The company's disclosures also reference its common stock and warrants trading on Nasdaq under CELU and CELUW.
Imugene Ltd and Celularity Inc have entered a research collaboration to explore the combination of Imugene’s CF33-CD19 oncolytic virus with Celularity’s CD19-targeting CAR T-cell therapy, CyCART-19, aimed at treating solid tumors. The partnership plans to initiate nonclinical studies in 2021, leveraging Celularity’s advanced T-cell therapy, which demonstrates sustained efficacy against tumors. The collaboration could potentially expand CAR T-cell therapy's application beyond hematological malignancies, enhancing treatment options for solid tumors. The first clinical trial is anticipated to start in 2022.
Celularity, Inc. announced the successful closing of its merger with GX Acquisition Corp., with gross proceeds of approximately $138 million. Common stock will trade on Nasdaq as CELU starting July 19, 2021. The company aims to innovate cancer treatment through placental-derived cell therapies, having multiple clinical programs for acute myeloid leukemia and glioblastoma. Notable partnerships with Palantir and Arthrex are also anticipated to enhance growth and revenue.